Not available
Quote | Huttig Building Products Inc. (NASDAQ:HBP)
Last: | $10.70 |
---|---|
Change Percent: | 0.19% |
Open: | $10.68 |
Close: | $10.70 |
High: | $10.7 |
Low: | $10.68 |
Volume: | 304,279 |
Last Trade Date Time: | 05/02/2022 04:53:26 pm |
News | Huttig Building Products Inc. (NASDAQ:HBP)
--News Direct-- Toronto, Ontario – TheNewswire – December 14, 2023 – Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based o...
(TheNewswire) Toronto, Ontario - TheNewswire - October 27, 2023 - Helix BioPharma Corp. (TSX:HBP) , (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immu...
Message Board Posts | Huttig Building Products Inc. (NASDAQ:HBP)
Subject | By | Source | When |
---|---|---|---|
$HBP all out on blow out earnings!!! | TrendTrade2016 | investorshub | 07/29/2021 2:04:40 PM |
beginning to move g/l | saj | investorshub | 07/29/2021 1:37:07 PM |
bought in this morning looks like a great | tomco | investorshub | 07/29/2021 11:29:55 AM |
nice earnings | saj | investorshub | 07/28/2021 11:13:39 PM |
$HBP the next home building monster | TrendTrade2016 | investorshub | 05/22/2021 10:28:08 AM |
News, Short Squeeze, Breakout and More Instantly...
Huttig Building Products Inc. Company Name:
HBP Stock Symbol:
NASDAQ Market:
Huttig Building Products Inc. Website:
--News Direct-- Toronto, Ontario – TheNewswire – December 14, 2023 – Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based o...
(TheNewswire) Toronto, Ontario - TheNewswire - October 27, 2023 - Helix BioPharma Corp. (TSX:HBP) , (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immu...
--News Direct-- Toronto, Ontario - TheNewswire - October 10, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immune-oncology antibody-drug-conjugate company developing an innovative drug platform for the treatment of cancer, announced today th...